Chuck Shih leads Pew’s drug spending research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments.
Prior to joining Pew, he held a fellowship in health policy at the National Pharmaceutical Council and George Washington University School of Public Health and Health Services.
Shih previously worked at the Centers for Medicare & Medicaid Services, where he was an analyst in the Coverage and Analysis Group and developed Medicare coverage policies for medical devices, pharmaceuticals, and procedures. He also served as a fellow at the Agency for Healthcare Research and Quality, where he advanced and implemented the Healthcare Horizon Scanning System, and served as a project officer for the creation of comparative effectiveness evidence reports and systematic reviews in the Effective Health Care Program.
Shih received a doctorate and master of health science degree from Johns Hopkins Bloomberg School of Public Health and a bachelor’s degree from Johns Hopkins University.
Recent WorkView All
Reverse payment agreements, also known as “pay-for-delay” deals, are settlements that involve a brand pharmaceutical manufacturer paying one or more potential generic competitors to resolve patent infringement lawsuits and agree upon a date by which the generic product can come to market. In fiscal year 2014 there were 21 such settlements involving 20 different branded drugs. Read More
Generic and biosimilar manufacturers, or drug developers, report that they have been unable to purchase samples of innovator drugs for their product development. Without access to these drugs, generic developers cannot conduct the testing required for Food and Drug Administration approval. They can sue brand companies for violating antitrust law, but this type of litigation can take years to... Read More
Allowing prescription drugs to be purchased and imported from abroad has the potential to lower health care costs in the U.S. In the short term, patients could access some medicines at lower prices, since brand pharmaceuticals are generally more expensive in the United States than in other high-income countries, in part because some nations have taken steps to limit drug prices. In the long term,... Read More